Vytenis Andriukaitis talks to Cancer Worlds Anna Wagstaff about what Europe needs to do to safeguard and extend access to high-quality cancer care in challenging times. How can European countries provide a rapidly rising number [more]
Showing that a new drug can keep advanced cancers from progressing, or stop early cancers from returning, is quicker, cheaper and easier than showing that it helps patients live longer. But how can we judge [more]
Paediatric oncologists are highly focused on how to minimise and manage the life-long damage their treatments inflict on young patients health. But for young survivors, the most immediate challenge is how to get an interrupted [more]
A great short piece by medical student Armaan Rowther flagging up the role of anatomy labs in shaping medics attitudes towards their future patients. “Is the language of medicine that is learned in anatomy lab [more]
Hopes of greatly speeding up the evaluation of new therapies by using tumour response to a short course of neoadjuvant treatment as a surrogate for clinical benefit have proved false and the sooner we recognise [more]
The patient rejects the standard of care. The oncologist cannot answer his question How long do I have? Is the treatment course they agree on second best, or best? This article was first published online [more]
Most people carrying harmful BRCA mutations only find out after they are diagnosed with cancer, and often not even then. Population screening is costly and the results can be hard to interpret. But should we [more]
Understanding the impact of treating the mother on the long-term health of her unborn child has long been held back by logistical and ethical obstacles to researching this rare patient population. Frédéric Amant took up [more]
The beta-carotene fiasco warned oncologists off suggesting supplements on the basis of observational studies. But with vitamin D now in the spotlight, how should doctors respond when their patients ask if it could help? A [more]
For many patients seeking access to treatments unavailable in their home country, the Cross-border Healthcare Directive turned out to be a bit of a disappointment. But a closer look shows it may help raise standards [more]
When chemotherapy drugs leak from the veins it can cause serious injury to the patient, greatly heighten their fears of undergoing future treatment cycles, and undermine their trust in their medical team. Knowing how to [more]
Can deep and close-knit collaboration between a handful of elite centres achieve what broader European research platforms and projects cannot? There has been talk about setting up a European cancer institute to rival the American [more]